Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCWB109
- Development stage
- Unknown
- Lead developer
- GC Wellbeing
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
GCWB109 is a probiotic health functional food ingredient developed by GC Green Cross Wellbeing. It consists of the specific lactic acid bacterium strain *Lactobacillus plantarum* GCWB1001 (also classified as *Lactiplantibacillus plantarum* GCWB1001), which was originally isolated from Korean kimchi. GCWB109 is designed to support respiratory health and reduce airway inflammation caused by environmental factors such as fine dust. In preclinical models of asthma, oral administration of the probiotic strain demonstrated protective effects by reducing the infiltration of inflammatory cells, suppressing the levels of pro-inflammatory cytokines (including TNF-alpha, IL-1beta, and IL-6), and inhibiting matrix metalloproteinase-9 (MMP-9) activity and oxidative stress. A Phase 2 clinical trial has evaluated its efficacy and safety in improving respiratory symptoms such as cough and breathlessness.
- Brand names
- Ur.PNT 숨쉬는 어린이 유산균숨쉬는 어린이 유산균
- Other names
- Lactiplantibacillus plantarum GCWB1001Lactobacillus plantarum GCWB1001
Beyond the preview
Go deeper on GCWB109.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GCWB109.